Therapeutics
Exploring the latest in Therapeutics.
An analytical overview of five critical medtech trends for 2026, including China's VBP expansion, the shift to outpatient care, supply chain resilience, GLP-1 therapy ripple effects, and platform-based competition.
An analysis of the global lung cancer market, highlighting the role of precision oncology, targeted therapies, and diagnostics in driving growth toward $72.97 billion by 2035.
Biogen validates anti-tau approach at AAIC, psychedelics full speed ahead, ATTR-CM shakeup
At AAIC 2026, Biogen presented promising anti-tau data for diranersen, while psychedelics advance with Compass positive results and FDA guidance. Meanwhile, ATTR-CM faces a setback as AstraZeneca and Ionis' Wainua fails a Phase 3 trial.
Global Medicine Use Trends to 2030: China's Rise, Specialty Therapies, and the Shift from Volume to Value
When Data Goes Dark: How Automated Content Filters Disrupt Healthcare Market Intelligence
Drug Therapy Development Explained: 5 Stages, Costs, Timelines, and the New AI-Driven R&D Shift
The Fast Track Paradox: Unpacking Clinical Development Times for FDA-Approved Drugs (2010–2020)
The Hidden Cost of Failure: How Basic Biological Research Can Reshape Drug Therapy Development
Drug Therapy Development Trends: Insights from 20 Volumes of 'Drug Design, Development and Therapy'
Navigating the Complexities of CNS Drug Development: From Animal Models to Human-Centric Strategies
Beyond Fixed Dosing: The Drug Titration Paradox and the Case for Personalized Medicine Strategies
The Billion-Dollar Pipeline: Unpacking the Economic and Strategic Logic of Modern Drug Development
From Omics to AI: The Evolving Economic and Technological Architecture of Cancer Drug Development
Beyond the Lab Bench: The Invisible Supply Chain Logic Reshaping Drug Therapy Development
The Crushing Economics of Alzheimer’s Drug Development: Why 100% Failure Rates Signal a Systemic Crisis
The 12% Reality: Unpacking the Economic and Strategic Logic Behind Drug Development Phases
Roche's Pipeline Pivot: Navigating Biosimilar Erosion with a Dual Bet on Cancer and Obesity
Beyond the 65% Surge: How Nektar's Rezpegaldesleukin Could Reshape the Alopecia Areata Treatment Paradigm
Beyond mRNA and Gene Therapy: How Serif's 'Modified DNA' Aims to Redefine Biotech's Next Frontier
Beyond the Headline: The Strategic Significance of Erica Schwartz's Appointment to Lead the CDC
Biotech's Pivot: Workforce Cuts, Asset Reacquisitions & Leadership Shifts Signal Industry Realignment
Beyond Weight Loss: How Eli Lilly's Orforglipron Heart Safety Data Reshapes the Obesity Drug Market
Beyond the Merger: How Obsidian's Reverse Takeover Signals a New Era for Financially-Strapped Biotechs
Beyond the $1.2B Deal: How UCB's Neurona Acquisition Signals a Paradigm Shift in Epilepsy Treatment
Beyond the Deal: How Eli Lilly's CrossBridge Bio Acquisition Reveals the New ADC Arms Race
Beyond Stelara: How Johnson & Johnson's Q1 2026 Reveals a Strategic Pivot in Pharma's Post-Blockbuster Era
Beyond the Rash: The Hidden Design Flaws Dooming Dermatology Drug Trials and How to Fix Them
Beyond the $77M: How Crossbow's Series B Signals a Strategic Pivot in T-Cell Engager Therapeutics
Beyond the Pill: How J&J's Oral Psoriasis Drug Icotyde Signals a Strategic Shift in Autoimmune Therapeutics
Leveraging the success of pandemic vaccines, researchers are now repurposing mRNA platforms to develop personalized cancer treatments and therapies for rare diseases.